A Phase 1 Study of the Safety and Tolerability of CTX-10726

NCT07419841 ↗

Phase 1 Recruiting 70 enrolled Compass Therapeutics

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a Phase 1, open-label, first-in-human study of CTX-10726 monotherapy in patients with metastatic or locally advanced malignancies. The study will be conducted in 2 Cohorts: Cohort 1 Dose Escalation and Cohort 2 Dose Expansion.

Timeline

Start: 2026-05-28
Primary completion: 2028-04-01
Completion: 2028-11-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CTX-10726	Unknown	0.3 mg/kg	Intravenous
Subject	CTX-10726	Unknown	10 mg/kg	Intravenous

A Phase 1 Study of the Safety and Tolerability of CTX-10726

Summary

Timeline

Drugs

Indications